新京报于11月10日刊发调查报道《起底多款“透析蛋白粉”:普通固体饮料宣称肾透析患者专用》,揭露倍元星、乐析能、金维盖宝、领透析安能、膳能士LKMMK及FOSDUS析康力素等6款产品在电商平台涉嫌虚假宣传,将普通固体饮料或保健食品包装成肾透析患者专用产品 1。截至11月11日,上述涉事产品的原购买链接已全部下架,其中乐析能旗舰店的商品已被清空,部分经销商则通过更改账号隐私设置或删除违规描述的方式应对 1。记者已将相关线索举报至涉事企业所在地的市场监管部门,后续将持续跟进处理进展 1。
根据2021年市场监管总局发布的公告规定,固体饮料的标签不得通过文字或图案明示、暗示其适用于病人等特定人群 1。此外,依据GB 29922标准,肾病全营养配方食品被明确列为常见特定全营养配方食品,属于特医食品范畴 1。
Following an investigative report published by Beijing News on November 10 regarding multiple "dialysis protein powders" marketed as exclusive products for kidney dialysis patients, all original purchase links for the six implicated products have been removed from e-commerce platforms 1. The investigation revealed that these items, including brands such as Beiyuanxing, Lexineng, Jinweigaibao, Ling Touxian'anneng, Shannengshi LKMMK, and FOSDUS Xikanglisu, were primarily ordinary solid drinks or health foods falsely advertised with specific medical applications 1. By November 11, the situation had escalated to include the complete clearance of products from the Lexineng flagship store, while some dealers deleted non-compliant descriptions or adjusted their account privacy settings to obscure past listings 1.
The core issue lies in the violation of regulatory standards, specifically a 2021 announcement by the State Administration for Market Regulation which prohibits solid drink labels from using text or graphics to imply suitability for specific groups like patients 1. Additionally, the national standard GB 29922 classifies renal disease total nutritional formula food under the category of Foods for Special Medical Purposes (FSMP), distinguishing it clearly from general solid beverages 1. In response to these findings, journalists from Beijing News have reported the involved enterprises to the local market supervision departments where the companies are registered, indicating a continued effort to track the regulatory handling of this case 1.
评论
还没有评论,欢迎留下第一条。